If you trade biotechs you know this is common. I'm in guys
Sentiment: Strong Buy
Celladon Shares May Have Upside to $70
The developer of gene therapy for heart failure to announce pivotal trial results.
We are initiating coverage of Celladon with a Buy rating and target of $70.
The total annual cost of treating heart failure today is $39 billion in the U.S. alone. By virtue of investment in Celladon, a number of pharmaceutical companies have a front row seat to evaluate the significance of CUPID 2. We anticipate a licensing or a merger and acquisition (M&A) transaction, if results are promising for future success
DD From Last Data:
CUPID data show that heart failure, which is a progressive disease, became stabilized in MYDICAR-treated patients: heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function significantly improved or remained the same while these parameters deteriorated substantiallywith ptientstreated with placebo and concurrent optimal drug and device therapy.The safety profile from thisstudy was very favorable, with no significant side-effects from MYDICAR® therapy L
CyberArk Software, Ltd. (NASDAQ:CYBR) The IDC MarketScape assesses vendors offering products in the privileged access administration (PAM) market and notes that, “CyberArk is the “big gorilla” with the most proceed and largest customer base.”
Juno Therapeutics Article : Immune System Drugs, CAR-Ts Melt Tumors In New Study, Leading A Cancer Revolution
Update on Advaxis Announces 1-for-125 Reverse Stock Split and Decrease in Authorized Shares ofCommon StockJuly 16, 2013 08:45 AM Eastern Daylight Time
do the DD
do the dd